Market capitalization | €266.18m |
Enterprise Value | €293.93m |
PER (TTM) P/E ratio | 14.70 |
EV/FCF (TTM) EV/FCF | 12.55 |
EV/Sales (TTM) EV/Sales | 2.74 |
P/S ratio (TTM) P/S ratio | 2.48 |
P/B ratio (TTM) P/B ratio | 5.96 |
Dividend yield | 6.13% |
Last dividend (FY24) | €1.36 |
As a Free StocksGuide user, you can view scores for all 6,945 stocks worldwide.
2 Analysts have issued a Pharmasgp Holding forecast:
2 Analysts have issued a Pharmasgp Holding forecast:
Mar '24 |
+/-
%
|
||
Net Profit | 18 18 |
38%
38%
|
|
Depreciation and Amortization | 9.39 9.39 |
1%
1%
|
|
Stock Compensation | - - |
-
|
|
Operating Cash Flow | 23 23 |
9%
9%
|
|
Investments | 1.28 1.28 |
106%
106%
|
|
Dividend Paid | 5.88 5.88 |
9%
9%
|
|
Free Cash Flow | 23 23 |
9%
9%
|
In millions EUR.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
PharmaSGP Holding SE engages in the manufacture of non-chemical, over-the-counter pharmaceutical products. Its product brands include RubaXX, Restaxil, FULMINAN, DESEO, Neradin, and TAUMEA. The company is headquartered in Gräfelfing, Germany.
Head office | Germany |
CEO | Natalie Weigand |
Employees | 89 |
Founded | 2012 |
Website | pharmasgp.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.